{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T15:15:15Z","timestamp":1770218115175,"version":"3.49.0"},"reference-count":36,"publisher":"Wiley","issue":"1-2","license":[{"start":{"date-parts":[[2015,1,26]],"date-time":"2015-01-26T00:00:00Z","timestamp":1422230400000},"content-version":"vor","delay-in-days":25,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Aust Veterinary J"],"published-print":{"date-parts":[[2015,1]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To investigate whether selected drug combinations used to treat rapidly growing mycobacteria (<jats:styled-content style=\"fixed-case\">RGM<\/jats:styled-content>) have drug\u2013drug interactions that affect efficacy and to investigate each isolate's susceptibility to cefovecin and clofazimine, individually.<\/jats:p><\/jats:sec><jats:sec><jats:title>Design<\/jats:title><jats:p>In vitro susceptibility testing of bacterial isolates.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Initially, five feline isolates and one canine isolate from both<jats:italic><jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>ycobacterium fortuitum<\/jats:italic>and<jats:italic><jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>. smegmatis<\/jats:italic>clusters (n = 12) underwent microbroth susceptibility testing to individual drugs to establish minimum inhibitory concentrations (<jats:styled-content style=\"fixed-case\">MIC<\/jats:styled-content>) of cefovecin, ciprofloxacin, clarithromycin, clofazimine, doxycycline, enrofloxacin, trimethoprim and sulfanilamide (the latter two as a combination). Checkerboard assays were then performed for susceptible<jats:italic><jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>. smegmatis<\/jats:italic>isolates for the following combinations: clarithromycin (one isolate only) versus enrofloxacin, clarithromycin vs doxycycline, clarithromycin vs trimethoprim\/sulfanilamide; enrofloxacin vs doxycycline (six isolates); enrofloxacin vs trimethoprim\/sulfanilamide (six isolates). Susceptible<jats:italic><jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>. fortuitum<\/jats:italic>isolates were tested against enrofloxacin versus doxycycline (four isolates only).<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>All six<jats:italic><jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>. fortuitum<\/jats:italic>isolates were susceptible to enrofloxacin, but only four of six were susceptible to doxycycline. All six<jats:italic><jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>. smegmatis<\/jats:italic>isolates were susceptible to doxycycline, enrofloxacin and trimethoprim\/sulfanilamide. A single isolate from the 12, a<jats:italic><jats:styled-content style=\"fixed-case\">M<\/jats:styled-content>. smegmatis<\/jats:italic>isolate, was susceptible to clarithromycin. The fractional inhibitory concentration of each drug ranged from 0.64 to 1.84, indicating that neither synergism nor antagonism was evident. All 12 isolates were resistant to cefovecin. The clofazimine MIC<jats:sub>50<\/jats:sub>to inhibit isolate growth was approximately 3.3\u2009\u03bcg\/mL for both strains.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Drugs commonly used for treatment of<jats:styled-content style=\"fixed-case\">RGM<\/jats:styled-content>, when tested as combinations, do not appear to antagonise one another in vitro. Cefovecin is not efficacious for treatment of<jats:styled-content style=\"fixed-case\">RGM<\/jats:styled-content>infections.<\/jats:p><\/jats:sec>","DOI":"10.1111\/avj.12279","type":"journal-article","created":{"date-parts":[[2015,1,27]],"date-time":"2015-01-27T04:47:33Z","timestamp":1422334053000},"page":"40-45","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["In vitro interaction of some drug combinations to inhibit rapidly growing mycobacteria isolates from cats and dogs and these isolates' susceptibility to cefovecin and clofazimine"],"prefix":"10.1111","volume":"93","author":[{"given":"CJM","family":"Bennie","sequence":"first","affiliation":[{"name":"Faculty of Veterinary Science McMaster Building, B14 The University of Sydney NSW 2006 Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"JLK","family":"To","sequence":"additional","affiliation":[{"name":"Faculty of Veterinary Science McMaster Building, B14 The University of Sydney NSW 2006 Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"PA","family":"Martin","sequence":"additional","affiliation":[{"name":"Faculty of Veterinary Science McMaster Building, B14 The University of Sydney NSW 2006 Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M","family":"Govendir","sequence":"additional","affiliation":[{"name":"Faculty of Veterinary Science McMaster Building, B14 The University of Sydney NSW 2006 Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2015,1,26]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-5827.2004.tb00193.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1053\/jfms.2000.0051"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-0813.2010.00566.x"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.12.5699-5708.2003"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1177\/1098612X13489221"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jfms.2008.10.008"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1053\/jfms.2001.0189"},{"key":"e_1_2_7_9_1","first-page":"7","article-title":"The use of clofazimine as a treatment for Mycobacterium fortuitum in a cat","volume":"22","author":"Michaud A","year":"1994","journal-title":"Feline Pract"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2010.06.011"},{"key":"e_1_2_7_11_1","volume-title":"M24\u2010A2 susceptibility testing of mycobacteria, nocardiae, and other aerobic actinomycetes: approved standard","author":"Clinical and Laboratory Standards Institute","year":"2011"},{"key":"e_1_2_7_12_1","volume-title":"M100\u2010S22 performance standards for antimicrobial susceptibility testing: 22nd informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2012"},{"key":"e_1_2_7_13_1","first-page":"249","volume-title":"Antimicrobial therapy in veterinary medicine","author":"Prescott JF","year":"2006"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.29.5.951"},{"key":"e_1_2_7_15_1","volume-title":"VET01\u2010S2 performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals: 2nd informational supplement","author":"Clinical and Laboratory Standards Institute","year":"2013"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200604-571ST"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/3.5.898"},{"key":"e_1_2_7_18_1","first-page":"365","volume-title":"Antibiotics in laboratory medicine","author":"Pillai SK","year":"2005"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkg301"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.15.4.716-746.2002"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.vetmic.2011.06.001"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-0813.2008.00270.x"},{"key":"e_1_2_7_23_1","volume-title":"M31\u2010A3 performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals: approved standard","author":"Clinical and Laboratory Standards Institute","year":"2008"},{"key":"e_1_2_7_24_1","volume-title":"VET01\u2010A4 performance standards for antimicrobial disk and dilution susceptibility tests for bacteria isolated from animals: approved standard","author":"Clinical and Laboratory Standards Institute","year":"2013"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.2460\/javma.2002.221.1568"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1463-5224.2001.00182.x"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinids\/3.3.627"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/11.5.427"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/38.2.193"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-197803000-00005"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10096-012-1766-8"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2885.2006.00801.x"},{"key":"e_1_2_7_33_1","doi-asserted-by":"crossref","first-page":"457","DOI":"10.2460\/javma.1995.207.04.0457","article-title":"Treatment of localized Mycobacterium avium complex infection with clofazimine and doxycycline in the cat","volume":"207","author":"Kaufman AC","year":"1995","journal-title":"J Am Vet Med Assoc"},{"key":"e_1_2_7_34_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1751-0813.1998.tb10238.x"},{"key":"e_1_2_7_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0738-081X(99)00103-0"},{"key":"e_1_2_7_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2009.12.008"},{"key":"e_1_2_7_37_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-3164.2012.01104.x"}],"container-title":["Australian Veterinary Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Favj.12279","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/avj.12279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,6]],"date-time":"2024-06-06T20:58:04Z","timestamp":1717707484000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/avj.12279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,1]]},"references-count":36,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2015,1]]}},"alternative-id":["10.1111\/avj.12279"],"URL":"https:\/\/doi.org\/10.1111\/avj.12279","archive":["Portico"],"relation":{},"ISSN":["0005-0423","1751-0813"],"issn-type":[{"value":"0005-0423","type":"print"},{"value":"1751-0813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,1]]},"assertion":[{"value":"2014-06-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-01-26","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}